Table 2.
Baseline characteristics of patients treated surgically.
| Bud-negative (N = 23) | Bud-positive (N = 24) | High TSR (<50%) (N = 34) | Low TSR (≥50%) (N = 13) | |
|---|---|---|---|---|
| Major resection | 7 (30.4%) | 12 (50.0%) | 12 (35.3%) | 7 (53.8%) |
| Minor resection | 16 (69.6%) | 12 (50.0%) | 22 (64.7%) | 6 (46.2%) |
| Resection margin | ||||
| R0 | 19 (82.6%) | 16 (66.7%) | 27 (79.4%) | 8 (61.5%) |
| R1 | 1 (4.3%) | 2 (8.3%) | 0 (0.0%) | 3 (23.1%) |
| R2 | 1 (4.3%) | 1 (4.2%) | 2 (5.9%) | 0 (0.0%) |
| Postoperative chemo- or radiotherapy | 8 (34.8%) | 11 (45.8%) | 14 (41.2%) | 5 (38.5%) |
| ASG | ||||
| No complication | 7 (30.4%) | 8 (33.3%) | 10 (29.4%) | 5 (38.5%) |
| Minor complication | 8 (34.8%) | 11 (45.8%) | 12 (35.3%) | 7 (53.8%) |
| Major complication | 8 (34.8%) | 5 (20.8%) | 12 (35.3%) | 1 (7.7%) |
| Stage | ||||
| Stage I | 13 (56.5%) | 14 (58.3%) | 19 (55.9%) | 8 (61.5%) |
| Stage II | 9 (39.1%) | 7 (29.2%) | 11 (32.4%) | 5 (38.5%) |
| Stage III | 1 (4.3%) | 2 (8.3%) | 3 (8.8%) | 0 (0.0%) |
| Stage IV | 0 (0.0%) | 1 (4.2%) | 1 (2.9%) | 0 (0.0%) |
| Vascular invasion | ||||
| Yes | 6 (28.6%) | 8 (36.4%) | 10 (31.3%) | 4 (36.4%) |
| No | 15 (71.4%) | 14 (63.6%) | 22 (68.8%) | 7 (63.6%) |
| Tumour localisation | ||||
| Right lobe | 13 (56.5%) | 15 (62.5%) | 21 (61.8%) | 7 (53.8%) |
| Left lobe | 6 (26.1%) | 7 (29.2%) | 8 (23.5%) | 5 (38.5%) |
| Both lobes | 4 (17.4%) | 2 (8.3%) | 5 (14.7%) | 1 (7.7%) |
| Unifocal tumour | 19 (82.6%) | 20 (83.3%) | 28 (79.4%) | 12 (92.3%) |
| Tumour grade | ||||
| Grade I | 3 (13.0%) | 1 (4.2%) | 2 (5.9%) | 2 (15.4%) |
| Grade II | 14 (60.9%) | 15 (62.5%) | 19 (55.9%) | 10 (76.9%) |
| Grade III | 6 (25.1%) | 8 (33.3%) | 13 (38.2%) | 1 (7.7%) |
| Tumour size (mm), median (IQR) | 50.0 (35.0–100.0) | 50.0 (31.5–107.5) | 60.0 (32.5–100.0) | 50.0 (40.5–62.5) |
ASG Accordion Severity Grading.
No significant differences were observed between the groups.